Food-derived β-lactoglobulin nanofibrils: An efficacy, safe, and scalable solution to overcome oral insulin delivery challenges.

Xihua Liu, Shuangjian Li, Guodong Wu, Wenzhe Jia, Yiguo Zhao, Yapeng Fang, Yiping Cao

Abstract read

In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xihua LiuDepartment of Food Science & Engineering, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Shuangjian LiDepartment of Food Science & Engineering, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Guodong WuShanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.

Wenzhe JiaDepartment of Food Science & Engineering, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Yiguo ZhaoDepartment of Food Science & Engineering, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Yapeng FangDepartment of Food Science & Engineering, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Yiping CaoDepartment of Food Science & Engineering, School of Agriculture & Biology, Shanghai Jiao Tong University, Shanghai, 200240, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oral delivery of biologics presents a formidable challenge: achieving high bioavailability without compromising gastrointestinal barrier integrity or clinical scalability-a trilemma that remains unaddressed by existing chemical permeation enhancers, ligand-modified nanoparticles, or exosome platforms. Here, we repurpose β-lactoglobulin (BLG) nanofibrils that resolve this challenge through a unique "enhance-degrade-restore" mechanism. In vivo, these nanofibrils enable oral insulin bioavailability reaching 10.2-12.3 %, and long-term safety studies confirm the absence of intestinal damage. Mechanistic studies reveal that the nanofibrils facilitate Ca

Indexed as

Insulin bioavailabilityIntestinal barrier modulationOral peptide deliveryProtein nanofibrilsβ-lactoglobulin

Identifiers

PMID41377894

DOI10.1016/j.bioactmat.2025.11.020

PMCPMC12686822

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.